<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="286">
  <stage>Registered</stage>
  <submitdate>25/08/2005</submitdate>
  <approvaldate>1/09/2005</approvaldate>
  <actrnumber>ACTRN12605000256673</actrnumber>
  <trial_identification>
    <studytitle>The Effects of Individualised and Complex Homeopathic Treatment in Osteoarthritis using a Novel Research design</studytitle>
    <scientifictitle>A randomised phase III study to evaluate the effects of individualised and complex homeopathy in the treatment of osteoarthritis to improve pain, stiffness and physical function</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Homeopathic simplex
This preparation is individually prescribed after homeopathic interview. This could be any of the homeopathic medications (200C potency) manufactured by Brauer Natural Medicine. 
Sublingual administration on Day 1 of the 4-week treatment period.

2. Homeopathic complex 
The composition of the complex is a mixture comprising Actaea spicata 3X (Baneberry), Causticum 12X (Hydrated Lime), Rhus toxicodendron 12X (Poison oak), Kalmia latifolia 5C (Mountain laurel), Bryonia 6C (Wild Hops), Colocynthis 6C  (Bitter Cucumber), Dulcamara 6C (Deadly Nightshade), Ruta Graveolens 6C (Rue), Kali Carbonicum 6C (Potassium carbonate), Cimicifuga  racemosa 9C (Black Cohosh). 
Administration is 2 pumps sublinguallly tds for the 4-week treatment period.</interventions>
    <comparator>Placebo 
The placebo matching the active individualized homeopathic preparations will be administered as a dry pilule and is composed of sucrose. 
The placebo matching the homeopathic complex will be administered as per the oral spray and is composed of a water and alcohol solution.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The Western Ontario and McMasters Universities (WOMAC) OA index for hip and knee OA, a well validated instrument.  Validation studies have shown that shifts of around 20% in any of the WOMAC subscales of pain, stiffness and physical function are clinically significant.</outcome>
      <timepoint>Measured at week -4 (screening); week 0 (baseline) and week +4 (post-treatment)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>1. Comprehensive Osteoarthritis Test</outcome>
      <timepoint>Measured daily during washout and treatment phases.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>2. Short Form-12 (SF-12)</outcome>
      <timepoint>Measured pre and post-treatment.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>3. Paracetamol usage</outcome>
      <timepoint>Measured daily during washout and treatment phases.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects with a diagnosis of osteoarthritis (OA) of the hip or knee, with or without other joint involvement, as defined by:-hip/knee pain while standing, walking and/or in motion of at least 3 months duration, and-evidence of one or more of the following features in an X-ray picture: osteophytes, osteosclerosis, cysts, or joint space narrowing, and-a total WOMAC score of 30 or more at study commencement.Subjects willing to discontinue their current OA treatment for the duration of the study, commencing at least 4 weeks prior to their first visit. This includes treatment with intra-articular injections, corticosteroids, NSAIDs, non-prescription therapies, chondroprotective agents, occlusive dressings, physiotherapy, or orthopaedic technical measures.Subjects who have given their written informed consent.Female subjects of childbearing age who agree to continue using contraceptive measures for the duration of the study.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Severe false alignment of the axis of the knee or hip.Surgery of the knee or hip within the past 2 months or arthroscopy within the past 2 months.Administration of intra-articular injections (e.g. corticosteroids, chondroprotective agents) or treatment with any long acting osteoarthritic therapy within one month of the study commencement.Subjects who use lipolytic, fibrinolytic, anti-coagulent or anti-inflammatory agents or agents that influence platelet function (especially aspirin, aspirin-containing compounds and other NSAIDs) or complementary natural antiarthrotic agents. Infectious, inflammatory  rheumatic diseases (e.g. Ross River Fever, rheumatoid arthritis).Female subjects who are pregnant or lactating.Subjects who are unwilling to comply with the study.Subjects with contra-indications to the study medication.Subjects with any condition that, in the opinion of the investigators, might interfere with the evaluation of the study objective.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Study interventions were supplied in sealed numbered containers and dispensed by an independent dispenser.</concealment>
    <sequence>Randomisation code was generated in blocks using SPSS software.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>9/01/2003</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>135</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Australian Centre for Complementary Medicine Education and Research</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Brauer Natural Medicine</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to compare the effects of traditional homeopathic treatment, a generic homeopathic treatment with placebo on symptoms of osteoarthritis of the hip and/or knee.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Cross University</ethicname>
      <ethicaddress>Lismore, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Queensland University</ethicname>
      <ethicaddress>Brisbane, QLD</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Professor Steven Myers</name>
      <address>Rifle Range Rd
Lismore NSW 2480</address>
      <phone>+61 2 66203403</phone>
      <fax>+61 2 66203307</fax>
      <email>smyers@scu.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Don Baker</name>
      <address>Rifle Range Rd
Lismore NSW 2480</address>
      <phone>+61 2 66269288</phone>
      <fax>+61 2 66203307</fax>
      <email>dbaker10@scu.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>